Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab transmural healing study in Crohn's disease
2023-504040-34-01Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 13
01
Overview
Phase 3, open-label, single-arm trial of guselkumab in Crohn's disease, sponsored by Janssen Pharmaceutical. Primary endpoint: Transmural healing by MRI at Week 48. Planned start Nov 2024; status: authorised.
02
Drugs
guselkumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2023-504040-34-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504040-34-01.